From the Editor

Notes from Munich: Kidney Cancer Updates from ESMO 2018

Sumanta Kumar Pal
November 01, 2018

I’m back now from a short stay in Munich for ESMO 2018 – didn’t get much beer or bratwurst, but I did soak in as much of the meeting as I could. The conference spanned a full five days – a little too much for my clinical schedule to handle – but I did get my hands on the bulk of the important renal cell carcinoma (RCC) data from the meeting.  I’ve boiled it down to three brief bullet points:

READ MORE PREVIOUS ARTICLES

Sumanta Kumar Pal, MD

Sumanta (Monty) Kumar Pal, MD, is an internationally recognized leader in the area of genitourinary cancers, including kidney, bladder, and prostate cancer. He is the Co-director of City of Hope's Kidney Cancer Program and is the head of the kidney and bladder cancer disease. Dr. Pal sits on the Editorial Board for clinical genitourinary cancer and is a reviewer for multiple journals including The Journal of Clinical Oncology, The Journal of Urology, European Urology, and many others.

Beyond the Abstracts
Author insights on peer reviewed manuscripts
Conference Coverage
Recent data from conferences worldwide

ESMO 2018 Kidney Cancer

AUA 2018 Northeastern Section

FOIU 2018 Kidney Cancer

ASCO 2018 Renal Cancer

AUA 2018 Renal Cancer

EAU 2018 Kidney Cancer

ASCO GU 2018 Renal Cancer

ESMO 2017 Kidney Cancer

ASCO 2017 Renal Cancer

ASCO GU 2017 Kidney Cancer

@UroToday
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe